skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Leading provider of strategic solutions for pharmaceutical industry professionals, Informa Pharma Consulting, has appointed Richard Veal as Global Director.

Richard Veal joins the company with an impressive background in big pharma consulting, having previously been Director of Strategic Planning within leading healthcare communications firm Sudler & Hennessey. Prior to this, Veal was Vice-President at creative healthcare agency Digitas Health, where he was responsible for practice leadership across a portfolio of solid and blood cancer products spanning global and US markets.

In his new role, Veal will lead on Pharma Consulting’s solutions across all of its arms, from R&D strategy and commercial optimization, to portfolio management. He will also be spearheading the development of tailored, long-term business strategies for global clients including big pharma, mid-tier, generics and biotech organizations.

Veal has specialized knowledge of the oncology market and a wealth of experience in developing brand strategy, as well as pipeline, franchise and disease state planning, having worked with both global pharmaceutical giants and life science focused organizations.

He also brings new strategic and consultancy capabilities to Pharma Consulting, particularly around war gaming, brand positioning, strategic planning and executive workshops.

Tim Polack, Head of Consulting for Informa Business Intelligence, said: “With his expertise across an impressively broad range of specialisms, Richard will be incredibly valuable to the business. We pride ourselves on developing truly personalized solutions for our clients and Richard has a proven track-record when it comes to understanding a brand and advising on its position in the market. He is certainly the right man for the job.”

Commenting on his appointment, Veal said: “The company’s ambition is clear – to improve the strategic capabilities of the pharmaceutical industry as a whole. Its data-driven methods and use of business intelligence to inform company and market strategy is an innovative and effective approach, and is already making a significant impact for many global organizations.”

“Our vision is to be a true strategic partner to our customers,” commented Linda Blackerby, President of Informa Pharma Intelligence.” “Our Pharma Consulting team, led by Richard, is poised to help our customers drive strategic innovations in the pharmaceutical industry, with the ultimate goal of improving healthcare outcomes.”

“This vision is one that I deeply share,” said Veal, “and I look forward to building on the success that Informa Pharma Consulting has already had in the industry.”

 

About Informa Pharma Intelligence


Informa Pharma Intelligence powers a full suite of analysis products - Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivio – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.


With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit: pharmaintelligence.informa.com.

 

About Pharma Consulting


Pharma Consulting’s team of experts leverage Informa’s unique data and insights to provide customized analysis and strategic advice for pharmaceutical clients across the globe. For more information visit pharmaintelligence.informa.com/pharmaconsulting.

 

Contact:

Tim Polack
Head of Consulting
Tel: +44 (020) 701 75370
Email: time.polack@informa.com




Next steps

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: